Hailong Cheng

951 total citations · 1 hit paper
27 papers, 742 citations indexed

About

Hailong Cheng is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Hailong Cheng has authored 27 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 15 papers in Pediatrics, Perinatology and Child Health and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in Hailong Cheng's work include Epilepsy research and treatment (15 papers), Pharmacological Effects and Toxicity Studies (14 papers) and Neuroscience and Neuropharmacology Research (6 papers). Hailong Cheng is often cited by papers focused on Epilepsy research and treatment (15 papers), Pharmacological Effects and Toxicity Studies (14 papers) and Neuroscience and Neuropharmacology Research (6 papers). Hailong Cheng collaborates with scholars based in United States, Portugal and Austria. Hailong Cheng's co-authors include David Blum, Seth C. Hopkins, Kenneth S. Koblan, Robert Goldman, Antony Loebel, Justine Kent, John H. Krystal, Todd Grinnell, Jay Harvey and Michael R. Sperling and has published in prestigious journals such as New England Journal of Medicine, Neurology and CHEST Journal.

In The Last Decade

Hailong Cheng

27 papers receiving 722 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

2020 204 citations Kenneth S. Koblan, Justine Kent et al. profile →

Peers

Countries citing papers authored by Hailong Cheng

Since Specialization

Citations

This map shows the geographic impact of Hailong Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hailong Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hailong Cheng more than expected).

Fields of papers citing papers by Hailong Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hailong Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hailong Cheng. The network helps show where Hailong Cheng may publish in the future.

Co-authorship network of co-authors of Hailong Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Hailong Cheng. A scholar is included among the top collaborators of Hailong Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hailong Cheng. Hailong Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Effectiveness of SEP−363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study 2021 ·CNS Spectrums ·Christoph U. Correll, Kenneth S. Koblan, Seth C. Hopkins, Justine Kent, Hailong Cheng, Robert Goldman, Antony Loebel	10
2	138 Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia 2020 ·CNS Spectrums ·Kenneth S. Koblan, Seth C. Hopkins, Justine Kent, Hailong Cheng, Robert Goldman, Antony Loebel	6
3	Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy 2019 ·Epilepsia ·Robert Wechsler, Rodney A. Radtke, Michael C. Smith, David G. Vossler, (unknown), Eugen Trinka, Hailong Cheng, Todd Grinnell, David Blum, (unknown), (unknown), (unknown)	8
4	Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures 2019 ·Epilepsy Research ·Steve S. Chung, Saurabh R. Sinha, Aashit Shah, John M. Stern, Hailong Cheng, (unknown), Todd Grinnell, David Blum	5
5	Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures 2018 ·Epilepsy & Behavior ·Eva Andermann, Victor Biton, Selim R. Benbadis, Bassel F. Shneker, Aashit Shah, Mar Carreño, Eugen Trinka, Elinor Ben‐Menachem, Arnaud Biraben, (unknown), Helena Gama, Hailong Cheng, David Blum	11
6	Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures 2018 ·Epilepsy Research ·Bassel Abou‐Khalil, Pavel Klein, Aashit Shah, Philippe Ryvlin, Luigi Maria Specchio, Helena Gama, (unknown), David Blum, Todd Grinnell, Hailong Cheng, (unknown)	8
7	Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials 2017 ·Epilepsy & Behavior ·Victor Biton, Joanne Rogin, Gregory L. Krauss, Bassel Abou‐Khalil, José Rocha, (unknown), Helena Gama, Eugen Trinka, Christian E. Elger, Hailong Cheng, Todd Grinnell, David Blum	42
8	Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials 2017 ·Epilepsy Research ·Gregory L. Krauss, Victor Biton, Jay Harvey, Christian E. Elger, Eugen Trinka, Patrício Soares‐da‐Silva, Helena Gama, Hailong Cheng, Todd Grinnell, David Blum	10
9	Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial 2016 ·Epilepsy & Behavior ·Naama Levy‐Cooperman, Kerri A. Schoedel, Bijan Chakraborty, David Blum, Hailong Cheng	7
10	Changes in Quality of Life (QoL) and Depressive Symptoms in a Long-term Open-label Extension (OLE) of Eslicarbazepine Acetate (ESL) Monotherapy Studies in Adults with Refractory Partial-onset Seizures (POS) (P1.234) 2015 ·Neurology ·Frank Gilliam, Hailong Cheng, David Blum	2
11	Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study 2015 ·BMC Neurology ·(unknown), Mercedes Jacobson, Ladislav Pazdera, Perminder Bhatia, Todd Grinnell, Hailong Cheng, David Blum	48
12	A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers 2015 ·Clinical Pharmacology in Drug Development ·(unknown), (unknown), (unknown), David Blum, Hailong Cheng	6
13	Efficacy of Eslicarbazepine Acetate in Patients with Refractory Partial-Onset Seizures Treated With or Without Concomitant Carbamazepine: A Pooled Analysis of Three Phase III Controlled Studies (P3.239) 2014 ·Neurology ·Steve S. Chung, Gregory L. Krauss, Michael R. Sperling, Eugen Trinka, Mar Carreño, David Blum, Patrício Soares‐da‐Silva, (unknown), Todd Grinnell, Hailong Cheng	5
14	Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: Results of a phase III, double‐blind, randomized, placebo‐controlled trial 2014 ·Epilepsia ·Michael R. Sperling, Bassel Abou‐Khalil, Jay Harvey, Joanne Rogin, Arnaud Biraben, Carlo Andrea Galimberti, Pedro André Kowacs, Seung Bong Hong, Hailong Cheng, David Blum, Teresa Nunes, Patrício Soares‐da‐Silva, (unknown)	98
15	Debris Flow Initiation Mechanisms in Strong Earthquake Area 2012 ·Journal of Mountain Science ·(unknown), Chuan Tang, (unknown), (unknown), Yang Liu, Hailong Cheng, Wei Huang	1
16	Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2008 ·Medicine ·John P. Hanrahan, Donna R. Grogan, Rudolf A. Baumgartner, (unknown), Hailong Cheng, Peter Zimetbaum, Joel Morganroth	48
17	Weighted Phenotypic Susceptibility Scores Are Predictive of the HIV‐1 RNA Response in Protease Inhibitor–Experienced HIV‐1–Infected Subjects 2004 ·The Journal of Infectious Diseases ·Ronald Swanstrom, Ronald J. Bosch, David Katzenstein, Hailong Cheng, Hongyu Jiang, Nicholas S. Hellmann, Richard Haubrich, Susan A. Fiscus, Courtney V. Fletcher, Edward P. Acosta, Roy M. Gulick	22
18	Durability of Response to Treatment among Antiretroviral‐Experienced Subjects: 48‐Week Results from AIDS Clinical Trials Group Protocol 359 2002 ·The Journal of Infectious Diseases ·Roy M. Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward P. Acosta, Stephen W. Lagakos, Ronald Swanstrom, William W. Freimuth, Sally Snyder, (unknown), Margaret A. Fischl, Carla Pettinelli, David Katzenstein	11
19	Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359 2000 ·The Journal of Infectious Diseases ·Roy M. Gulick, X. Joan Hu, Susan A. Fiscus, Courtney V. Fletcher, Richard Haubrich, Hailong Cheng, Edward P. Acosta, Stephen W. Lagakos, Ronald Swanstrom, William W. Freimuth, Sally Snyder, (unknown), Margaret A. Fischl, Carla Pettinelli, David Katzenstein	73
20	Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 2000 ·AIDS ·Courtney V. Fletcher, Edward P. Acosta, Hailong Cheng, Richard Haubrich, Margaret A. Fischl, Ralph H. Raasch, (unknown), X. Joan Hu, David Katzenstein, Rory P. Remmel, Roy M. Gulick	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact